Quality Assurance vs Quality Control in Veterinary Pharmaceuticals

Quality Assurance (QA) and Quality Control (QC) are both essential in veterinary pharmaceutical manufacturing, but they serve distinct roles. Treating them as interchangeable obscures whether a manufacturer has genuinely mature quality systems or only the appearance of them. For distributors and importers evaluating a manufacturing partner, understanding the distinction helps you ask more precise questions and interpret answers with greater accuracy.

Defining Quality Assurance

Quality Assurance is the system-level discipline that ensures quality is planned, built, and maintained across an entire manufacturing operation — not only at the testing stage. QA owns the quality management system: written policies, Standard Operating Procedures (SOPs), change control processes, deviation and CAPA (Corrective and Preventive Action) management, supplier qualification, and internal audit programmes.

In pharmaceutical manufacturing, QA holds final batch release authority. Even if a batch passes all QC tests, QA can reject it if the manufacturing process deviated from its approved procedure in a way that could affect product integrity. This independence from production management is critical: quality decisions cannot be overridden by output targets. A manufacturer where the same person runs production and approves batch releases has a structural conflict of interest that no amount of QC testing can compensate for.

Defining Quality Control

Quality Control is the analytical testing function. QC receives samples from incoming raw materials, in-process stages, and finished products, and tests them against approved specifications using validated methods. Results are documented in QC reports and Certificates of Analysis. If a result is out of specification (OOS), QC initiates a formal investigation requiring root-cause analysis before any batch release decision can proceed.

QC does not approve batch release — that is the QA function. QC provides the analytical data that QA uses as part of its broader batch review. This structural separation — testing versus release — is a core GMP principle that prevents a single department from both running and evaluating its own work.

How QA and QC interact during batch manufacture

During manufacture of a veterinary medicine batch, a Batch Manufacturing Record (BMR) is completed in real time by production staff. At the end of the run, QC analyses retained samples against the finished-product specification. QA then reviews the completed BMR alongside QC results, checks for any open deviations or investigations, and makes the final release decision. Only batches approved by QA may enter the distribution supply chain.

• Raw material receipt: QC tests identity and quality; QA approves the supplier and releases materials for use.
• In-process controls: QC samples at defined production stages; results recorded in the BMR.
• Finished product testing: QC analyses potency, pH, appearance, dissolution (or solubility for powders), and other specification points.
• Batch release: QA reviews BMR plus all QC data, confirms no unresolved deviations, and approves or rejects the batch.
• Retained samples: kept at controlled storage conditions throughout the product shelf life for reference in complaint or recall investigations.

QA beyond the production floor: supplier qualification and change control

QA extends its governance to supplier qualification — the process of evaluating and approving vendors of raw materials and packaging. A veterinary medicine is only as reliable as its active ingredients and excipients. A raw material that fails specification may be visually indistinguishable from a compliant one. QA-managed approved supplier lists, with periodic re-evaluation, manage this risk systematically rather than ad hoc.

Change control is another QA-owned process. Any change to a validated manufacturing procedure — new equipment, a different raw material source, revised mixing parameters — must be formally assessed and approved before implementation. Uncontrolled changes are a primary source of batch-to-batch variability that end-product testing often cannot detect. When evaluating a manufacturer, ask specifically about their change control process and how raw material supplier changes are managed.

ISO 9001 and the quality management system

ISO 9001 is the international standard for quality management systems (QMS). It provides a documented framework for organisations to define, control, and continually improve their processes. For a pharmaceutical manufacturer, ISO 9001 certification from an accredited third-party body confirms the QA system has been externally reviewed — not only internally declared. Surveillance audits maintain the certification; lapses are visible in audit records.

ISO 9001 does not replace GMP compliance; it complements it. Together, a current GMP certificate and an active ISO 9001 certification provide a stronger picture of quality system maturity than either credential alone. The GMP certificate governs pharmaceutical-specific manufacturing requirements; ISO 9001 confirms the broader organisational quality framework is documented and audited.

What weak QA/QC looks like in practice

Weak quality systems share recognisable patterns that emerge during evaluation or, more expensively, after a distribution agreement is in place. Warning signs include: QA and production functions reporting to the same manager; batch records completed after the fact rather than in real time; deviations closed without documented root-cause investigation; OOS results invalidated without adequate justification; supplier changes made without QA approval; and batch documentation unavailable within a reasonable timeframe when requested.

These patterns typically only become visible when something goes wrong — a product complaint, a failed customer audit, or inconsistent field performance across batches. By then, affected product may already be distributed. Pre-qualification evaluation of a manufacturer's quality functions is always less costly than managing post-distribution quality failures.

Questions to ask a manufacturer about QA/QC functions

1. Are QA and QC independent departments with separate reporting lines from production management?
2. Who holds final authority to release or reject a batch — QA or production?
3. How are out-of-specification QC results investigated before a batch release decision is made?
4. What does your deviation and CAPA process look like — can you walk us through a recent non-critical example?
5. How do you qualify and periodically re-qualify raw material suppliers?
6. What change control process governs modifications to validated production methods or raw material sources?
7. Can you provide a sample Certificate of Analysis to show the format we would receive per batch?

Divine Pharmaceuticals quality structure

Divine Pharmaceuticals operates under documented quality management systems holding ISO 9001 certification alongside its DRAP GMP Certificate GMP/C/000153/52026, ISO 14001, and ISO 45001. Manufacturing and quality system information is available at Manufacturing and Quality & Compliance. Verified certificate and membership documents can be requested through Resources. For export and distribution evaluation inquiries, contact the commercial team via Export & Distribution or /contact?inquiry=export.

Authoritative references

See DRAP QA/LT guidelines for Pakistan regulatory quality frameworks, and WHO materials on pharmaceutical quality assurance and GMP for internationally recognised manufacturing quality principles.